@article{fcd671e290f44c9d8a7187915538dc6b,
title = "Antibody Responses to Schistosoma mansoni Schistosomula Antigens",
abstract = "While antigens from Schistosoma schistosomula have been suggested as potential vaccine candidates, the association between antibody responses with schistosomula antigens and infection intensity at reinfection is not well known. Schistosoma mansoni-infected individuals were recruited from a schistosomiasis endemic area in Uganda (n = 372), treated with 40 mg/kg praziquantel (PZQ) and followed up at five weeks and at one year post-treatment. Pre-treatment and five weeks post-treatment immunoglobulin (Ig) E, IgG1 and IgG4 levels against recombinant schistosomula antigens rSmKK7, rSmLy6A, rSmLy6B and rSmTSP7 were measured using ELISA. Factors associated with detectable pre-treatment or post-treatment antibody response against the schistosomula antigens and the association between five-week antibody responses and one year post-treatment reinfection intensity among antibody responders were examined. Being male was associated with higher pre-treatment IgG1 to rSmKK7, rSmLy6a and AWA. Five weeks post-treatment antibody responses against schistosomula antigens were not associated with one year post-treatment reinfection intensity among antibody responders{\textquoteright} antibody levels against rSmKK7, rSmLy6B and rSmTSP7 dropped, but increased against rSmLy6A, AWA and SEA at five weeks post-treatment among antibody responders. S. mansoni-infected individuals exhibit detectable antibody responses to schistosomula antigens that are affected by treatment. These findings indicate that schistosomula antigens induce highly varied antibody responses and could have implications for vaccine development.",
keywords = "Schistosoma mansoni, IgE, antibody responder, reinfection, schistosomula antigens, Enzyme-Linked Immunosorbent Assay, Humans, Schistosomiasis mansoni/drug therapy, Male, Immunoglobulin E/immunology, Animals, Anthelmintics/administration & dosage, Immunoglobulin G/immunology, Praziquantel/administration & dosage, Helminth Proteins/genetics, Schistosoma mansoni/genetics, Antibody Formation, Female, Uganda, Antigens, Helminth/immunology, Antibodies, Helminth/immunology",
author = "Moses Egesa and Lawrence Lubyayi and Jones, {Frances M.} and {van Diepen}, Angela and Iain Chalmers and Tukahebwa, {Edridah M.} and Bagaya, {Bernard S.} and Hokke, {Cornelis H.} and Karl Hoffmann and Dunne, {David W.} and Elliot, {Alison M.} and Maria Yazdanbakhsh and Shona Wilson and Stephen Cose",
note = "Funding Information: Wellcome Trust Uganda PhD Fellowship in Infection and Immunity; Wellcome Trust Strategic Award, Grant/Award Number: 084344 and 107743; DELTAS Africa Initiative, Grant/Award Number: 107743; TheSchistoVac, Grant/Award Number: 242107; European Community{\textquoteright}s Seventh Framework Programme, Grant/Award Number: FP7-Health-2009-4.3.1-1 Funding Information: We are grateful to the participants and authorities of Namoni for their participation and cooperation in this study. We value the work done by the field team from the Vector Control Division, Uganda Ministry of Health and Kenya Medical Research Institute, Nairobi. ME was supported by a Wellcome Trust Uganda PhD Fellowship in Infection and Immunity funded by a Wellcome Trust Strategic Award (Grant No. 084344) and through the DELTAS Africa Initiative (Grant No. 107743). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (Grant No. 107743) and the UK government. The views expressed in this publication are those of the author(s) and not necessarily those of AAS, NEPAD Agency, Wellcome Trust or the UK government. ME also received support from TheSchistoVac (Grant No. 242107) under the European Community's Seventh Framework Programme (FP7-Health-2009-4.3.1-1). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Funding Information: We are grateful to the participants and authorities of Namoni for their participation and cooperation in this study. We value the work done by the field team from the Vector Control Division, Uganda Ministry of Health and Kenya Medical Research Institute, Nairobi. ME was supported by a Wellcome Trust Uganda PhD Fellowship in Infection and Immunity funded by a Wellcome Trust Strategic Award (Grant No. 084344) and through the DELTAS Africa Initiative (Grant No. 107743). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS){\textquoteright}s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa{\textquoteright}s Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (Grant No. 107743) and the UK government. The views expressed in this publication are those of the author(s) and not necessarily those of AAS, NEPAD Agency, Wellcome Trust or the UK government. ME also received support from TheSchistoVac (Grant No. 242107) under the European Community{\textquoteright}s Seventh Framework Programme (FP7-Health-2009-4.3.1-1). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Publisher Copyright: {\textcopyright} 2018 The Authors. Parasite Immunology Published by John Wiley & Sons Ltd",
year = "2018",
month = nov,
day = "28",
doi = "10.1111/pim.12591",
language = "English",
volume = "40",
journal = "Parasite Immunology",
issn = "0141-9838",
publisher = "Wiley",
number = "12",
}
